v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating activities:    
Net (loss) income $ (8,111) $ 2,635
Adjustments to reconcile net (loss) income to net cash used in operating activities:    
Stock-based compensation expense 2,976 2,511
Depreciation and amortization 529 551
Amortization of debt discount and debt issuance costs 220 211
Accretion of discount on short-term investments (144) (281)
Retirement and impairment of property and equipment 7 0
Gain on disposal of property and equipment 0 (34)
Change in operating assets and liabilities:    
Accounts receivable 5,894 145
Inventory (169) (3,772)
Prepaid expenses and other assets 1,122 (8,604)
Accounts payable (24) 624
Accrued clinical and manufacturing liabilities (611) (5,466)
Accrued payroll and employee related liabilities (2,880) (3,103)
Other accrued expenses (349) 5,713
Net cash used in operating activities (1,540) (8,870)
Investing activities:    
Purchases of short-term investments (13,139) (22,902)
Maturities and sales of short-term investments 12,591 25,242
Purchases of property and equipment (391) (109)
Proceeds from sale of property and equipment   42
Net cash (used in) provided by investing activities (939) 2,273
Financing activities:    
(Payments) receipts for stock issued under the equity incentive plan (51) 64
Net cash (used in) provided by financing activities (51) 64
Net decrease in cash and cash equivalents (2,530) (6,533)
Cash and cash equivalents at beginning of period 28,647 25,802
Cash and cash equivalents at end of period 26,117 19,269
Supplemental disclosure of cash flow information:    
Interest paid $ 2,627 $ 636